The European Commission's Directorate General for Competition, the United States’ Federal Trade Commission (“FTC”), the Canadian Competition Bureau, and the UK's Competition and Markets Authority, launched a joint public consultation today in the field of pharmaceutical mergers. The purpose of this consultation is to gather ideas and views from all stakeholders in the field. These contributions will then feed into a workshop that will be organised by the Working Group.
The FTC will collect and publish all contributions and comments on behalf and in close cooperation with the members of the Working Group. Interested parties can respond to the consultation until 25 June 2021. You will find the public consultation here.
- 11 maj 2021